Replimune Group, Inc. (REPL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol REPL
- Company Replimune Group, Inc.
- Price $17.39
- Changes Percentage 8.28
- Change 1.33
- Day Low $16.2
- Day High $17.78
- Year High $16.33
- Year Low $1.5
- Market Cap $1,058,728,482
- Price Avg 50 EMA (D) $12.79
- Price Avg 200 EMA (D) $8.82
- Exchange NASDAQ
- Volume 2,578,548
- Average Volume 4,381,036
- Open $16.27
- Previous Close $16.06
- EPS -3.15
- PE -4.00
- Earnings Announcement 2026-11-05 05:00:00
- Shares Outstanding $84,026,070
Company brief: REPLIMUNE GROUP, INC. (REPL )
- Healthcare
- Biotechnology
- Dr. Sushil Patel Ph.D.
- https://www.replimune.com
- US
- N/A
- 07-20-2018
- US76029N1063
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.